- Leading pharmaceutical company, a pioneer in analgesic/anti-inflammatory patch manufacturing. Expanding to over 50 countries world-wide.
- We specialize in “Pain” and “Transdermal”, via the analgesic/anti-inflammatory patch manufacturing technologies that we have developed since establishment of the company.
For “Pain”, we have developed the analgesic products “to release humans from pain” as our motto; and for “Transdermal”, we have developed transdermal products to deliver drugs across the skin barrier, and are not limited to the analgesic/anti-inflammatory field.
Also, due to global unmet needs and demands, we have successfully expanded the market internationally, and have made significant contributions to the QOL (Quality of Life) of consumers world-wide.
- President and CEO Misako Fujioka Interviewed in Newsweek International
- Change in The Board of Directors
- Notice of Launch of ALLYDONE® Patches 27.5 mg / ALLYDONE® Patches 55 mg in Japan as Japan’s First Donepezil Transdermal Therapeutic System
- Manufacturing and Marketing Approval Received in Japan for ALLYDONE® Patches for Treatment of Dementia Due to Alzheimer’s Disease as Japan’s First Donepezil Transdermal Therapeutic System
- Execution of a license agreement on an exclusive marketing right in Japan of the first donepezil transdermal therapeutic system in Japan
- TEIKOKU SEIYAKU was selected as A Global Niche Top Company by METI in FY2020.